633303-36-3

Upstream product

• 596-43-0 bromo-triphenyl-methane 
• 16676-32-7 (4'R,4a'S,7a'R,12b'S)-3'-(cyclopropylmethyl)-1',2',3',4',5',6'-hexahydro-4a'H,7a'H-spiro[[1,3]dioxolane-2,7'-[4,12]methanobenzofuro[3,2-e]isoquinoline]-4a',9'-diol 

Downstream Products

• 633303-33-0 17-(cyclopropylmethyl)-4,5α-epoxy-14β-[(2-methylbenzyl)oxy]-3-hydroxymorphinan-6-one 
• 646032-66-8 17-(cyclopropylmethyl)-4,5α-epoxy-14β-[(2-methylbenzyl)oxy]-3-(triphenylmethoxy)morphinan-6-one ethane-1,2-diyl acetal 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 14-alkoxymorphinans. Part 19: Effect of 14-O-benzylation on the opioid receptor affinity and antagonist potency of naltrexone

The 14-O-benzylnaltrexones 3-6 were prepared from naltrexone (2) in several steps. The novel compounds were biologically evaluated in radioligand binding and in [35S]GTPγS functional assays in comparison to the reference compound naltrexone. In the binding assay, compounds 3-6 exhibited preference for κ opioid receptors, while the parent compound naltrexone shows preference for μ receptors. In the functional assay, μ antagonist potency of compounds 3-6 was in the range of naltrexone, while K antagonist potency was considerably higher for most novel compounds in comparison to naltrexone.

MORPHINAN DERIVATIVES THE QUATERNARY AMMONIUM SALTS THEREOF SUBSTITUTED IN POSITION 14, METHOD FOR PRODUCTION AND USE THEREOF

The invention relates to a class of morphinan compounds and the quaternary ammonium salts thereof, substituted in position 14, which may be used as highly-active analgesics or also as opioid antagonists. The invention further relates to the pharmaceutically-acceptable salts and easily-produced derivatives thereof, a process for production thereof and use thereof in the production of pharmaceutical specialities.